Evidence map›Paper›PMID 38267402›Full record

ArticleNature communications2024

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.

Isaac Dean, Colin Y C Lee, Zewen K Tuong, Zhi Li, Christopher A Tibbitt, Claire Willis, Fabrina Gaspal, Bethany C Kennedy, Veronika Matei-Rascu, Rémi Fiancette and 12 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
33.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 138 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  7. Article
  8. Article
  9. Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Isaac DeanInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-4750-5335
Colin Y C LeeDepartment of Medicine, Molecular Immunity Unit, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8380-4917
Zewen K TuongDepartment of Medicine, Molecular Immunity Unit, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-6735-6808
Zhi LiInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-0583-1116
Christopher A TibbittCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Claire WillisInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Fabrina GaspalInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Bethany C KennedyInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0001-9529-7545
Veronika Matei-RascuInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Rémi FiancetteInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-1531-9770
Caroline NordenvallDepartment of Molecular Medicine and Surgery, Karolinska Institutet and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
Ulrik LindforssDepartment of Molecular Medicine and Surgery, Karolinska Institutet and Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
Syed Murtuza BakerDivision of Informatics, Imaging & Data Science, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0002-6633-333X
Christian StockmannInstitute of Anatomy, University of Zurich, Zurich, Austria.
Veronika SexlInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Scott A HammondEarly Oncology R&D, AstraZeneca, MD, USA.ORCID 0000-0001-5800-4328
Simon J DovediEarly Oncology R&D, AstraZeneca, UK.
Jenny MjösbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-1119-0976
Matthew R HepworthLydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0002-9613-7858
Gianluca CarlessoEarly Oncology R&D, AstraZeneca, MD, USA.
Menna R ClatworthyDepartment of Medicine, Molecular Immunity Unit, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK. mrc38@medschl.cam.ac.uk.ORCID 0000-0002-3340-9828
David R WithersInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. d.withers@bham.ac.uk.ORCID 0000-0003-3757-7594
University of Birmingham · GBKarolinska University Hospital · SEMRC Laboratory of Molecular Biology · GBAstraZeneca (United States) · USManchester Academic Health Science Centre · GBAstraZeneca (United Kingdom) · GBKarolinska Institutet · SEUniversity of Veterinary Medicine Vienna · AT

Funding

Cancer Research UK 27535Medical Research Council MR/S035842/1Wellcome TrustWellcome Trust 105644/Z/14/ZWellcome Trust 110199/Z/15/ZWellcome Trust 220268/Z/20/ZWorldwide Cancer Research 21-0073
6 · The paper itself

Abstract

Immune cell dysfunction within the tumor microenvironment (TME) undermines the control of cancer progression. Established tumors contain phenotypically distinct, tumor-specific natural killer (NK) cells; however, the temporal dynamics, mechanistic underpinning and functional significance of the NK cell compartment remains incompletely understood. Here, we use photo-labeling, combined with longitudinal transcriptomic and cellular analyses, to interrogate the fate of intratumoral NK cells. We reveal that NK cells rapidly lose effector functions and adopt a distinct phenotypic state with features associated with tissue residency. NK cell depletion from established tumors did not alter tumor growth, indicating that intratumoral NK cells cease to actively contribute to anti-tumor responses. IL-15 administration prevented loss of function and improved tumor control, generating intratumoral NK cells with both tissue-residency characteristics and enhanced effector function. Collectively, our data reveals the fate of NK cells after recruitment into tumors and provides insight into how their function may be revived.

Indexed as

Internship and ResidencyNeoplasmsGene Expression ProfilingHumansKiller Cells, NaturalTranscriptomeTumor Microenvironment

Identifiers

PMID38267402
PMCPMC10808449
OpenAlexW4391169033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.